HomeCompareZTLLF vs ABBV

ZTLLF vs ABBV: Dividend Comparison 2026

ZTLLF yields 18779.34% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZTLLF wins by $28092078350658744320.00M in total portfolio value
10 years
ZTLLF
ZTLLF
● Live price
18779.34%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28092078350658744320.00M
Annual income
$27,800,862,069,237,315,000,000,000.00
Full ZTLLF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ZTLLF vs ABBV

📍 ZTLLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZTLLFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZTLLF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZTLLF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZTLLF
Annual income on $10K today (after 15% tax)
$1,596,244.13/yr
After 10yr DRIP, annual income (after tax)
$23,630,732,758,851,720,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ZTLLF beats the other by $23,630,732,758,851,720,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZTLLF + ABBV for your $10,000?

ZTLLF: 50%ABBV: 50%
100% ABBV50/50100% ZTLLF
Portfolio after 10yr
$14046039175329372160.00M
Annual income
$13,900,431,034,618,658,000,000,000.00/yr
Blended yield
98.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ZTLLF
No analyst data
Altman Z
-352.3
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZTLLF buys
0
ABBV buys
0
No recent congressional trades found for ZTLLF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZTLLFABBV
Forward yield18779.34%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$28092078350658744320.00M$102.3K
Annual income after 10y$27,800,862,069,237,315,000,000,000.00$24,771.77
Total dividends collected$28072852724837646336.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ZTLLF vs ABBV ($10,000, DRIP)

YearZTLLF PortfolioZTLLF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,888,634$1,877,934.27$11,550$430.00+$1.88MZTLLF
2$333,491,028$331,470,189.51$13,472$627.96+$333.48MZTLLF
3$55,058,052,217$54,701,216,816.58$15,906$926.08+$55058.04MZTLLF
4$8,499,056,929,068$8,440,144,813,196.32$19,071$1,382.55+$8499056.91MZTLLF
5$1,226,725,885,394,009$1,217,631,894,479,905.50$23,302$2,095.81+$1226725885.37MZTLLF
6$165,563,977,411,135,700$164,251,380,713,764,160.00$29,150$3,237.93+$165563977411.11MZTLLF
7$20,894,950,430,861,460,000$20,717,796,975,031,546,000.00$37,536$5,121.41+$20894950430861.42MZTLLF
8$2,465,986,702,596,758,000,000$2,443,629,105,635,736,000,000.00$50,079$8,338.38+$2465986702596758.00MZTLLF
9$272,164,748,991,990,740,000,000$269,526,143,220,212,230,000,000.00$69,753$14,065.80+$272164748991990752.00MZTLLF
10$28,092,078,350,658,745,000,000,000$27,800,862,069,237,315,000,000,000.00$102,337$24,771.77+$28092078350658744320.00MZTLLF

ZTLLF vs ABBV: Complete Analysis 2026

ZTLLFStock

Zonetail Inc. provides a mobile platform to hotels and condominiums Its mobile platforms connect the guests of a hotel and the residents of high-rise buildings to the amenities and services of their building through their mobile devices. The company is based in Toronto, Canada.

Full ZTLLF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ZTLLF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZTLLF vs SCHDZTLLF vs JEPIZTLLF vs OZTLLF vs KOZTLLF vs MAINZTLLF vs JNJZTLLF vs MRKZTLLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.